S.Amdt. 2442Senate118th Congress (2023-2025)
S.Amdt. 2442
Sponsored by
Sen. Marco Rubio (R-FL)
Submitted July 11, 2024
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Floor
Latest Action
Senate amendment submitted
July 11, 2024
Text
Submitted
SA 2442. Mr. RUBIO submitted an amendment intended to be proposed by him to the bill S. 4638, to authorize appropriations for fiscal year 2025 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; which was ordered to lie on the table; as follows: At the end of subtitle H of title X, insert the following: SEC. 1095. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MANUFACTURING CAPABILITIES. (a) In General.--The Secretary of Health and Human Services (referred to in this section as the ``Secretary''), in cooperation with the Director of the Biomedical Advanced Research and Development Authority, shall seek to enter into an agreement with the National Institute for Innovation in Manufacturing Biopharmaceuticals to perform the services described in subsection (b). (b) Review and Recommendations.--Under an agreement described in subsection (a) between the Secretary, the Director of the Biomedical Advanced Research and Development Authority, and the National Institute for Innovation in Manufacturing Biopharmaceuticals, the National Institute for Innovation in Manufacturing Biopharmaceuticals shall-- (1) review current domestic biopharmaceutical manufacturing capacity at the Department of Health and Human Services and such department's adaptability to various threats; (2) draft recommendations for developing, demonstrating, deploying, and advancing new domestic biopharmaceutical manufacturing technologies that address gaps identified under paragraph (1) and align Federal technologies with technologies available to the private sector, including through the new BioMAP initiative of the Biomedical Advanced Research and Development Authority; and (3) identify other opportunities and priorities to improve the United States public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities. ______